Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
Andrew Allen tapped to lead cancer immunotherapy developer Gritstone |
|||||||||||||||||||
With $102 million in Series A funding, Gritstone Oncology publicly launched this week to develop personalized cancer vaccines. The company, which will split operations between San Francisco and Cambridge, MA, will be helmed by Dr. Andrew Allen, former Clovis Oncology ($CLVS) co-founder and chief medical officer. Versant Ventures led the funding, with managing partner Tom Woiwode saying in a statement that the company has the "utmost confidence" in Allen's ability, "and that of his team, to tackle this challenge of developing next-generation immune-oncology products." Prior to Clovis, Allen served as chief medical officer of Pharmion for two years. Story | Release
|